Tidal Investments LLC Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

Tidal Investments LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 22.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,668 shares of the company's stock after acquiring an additional 3,458 shares during the period. Tidal Investments LLC's holdings in Zoetis were worth $3,042,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after buying an additional 120,158 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after buying an additional 190,137 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after buying an additional 1,116,541 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after buying an additional 3,059,255 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Zoetis by 13.3% in the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after buying an additional 755,893 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Zoetis Stock Performance

Zoetis stock traded up $3.20 during trading hours on Tuesday, reaching $165.78. 534,343 shares of the stock were exchanged, compared to its average volume of 3,032,797. The stock has a market cap of $73.81 billion, a P/E ratio of 30.31, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The firm's 50 day moving average is $156.47 and its 200 day moving average is $164.68.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis's dividend payout ratio (DPR) is currently 35.91%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Finally, Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.